• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨质疏松性骨折患者的继发性骨质疏松症。

Secondary osteoporosis in patients with an osteoporotic fracture.

机构信息

Kolling Institute, University of Sydney, St Leonards, Sydney 2065, Australia.

出版信息

Best Pract Res Clin Rheumatol. 2009 Dec;23(6):769-79. doi: 10.1016/j.berh.2009.09.006.

DOI:10.1016/j.berh.2009.09.006
PMID:19945688
Abstract

Secondary osteoporosis is a common cause of osteoporosis, and there are many medical conditions associated with osteoporosis. Many of these present well before osteoporosis develops, and knowledge of these pre-existing conditions may influence the decision about whether to test and/or treat for osteoporosis. Men and premenopausal women with unexplained osteoporosis or a history of fragility fracture should undergo investigation for secondary osteoporosis. Postmenopausal women with risk factors for secondary osteoporosis should also be carefully evaluated. Beyond the well-recognised association with glucocorticoids, an increasing list of drugs has been implicated in causing bone loss and fractures. With appropriate consideration of secondary causes and relevant investigations, many of these conditions are preventable with newer therapies.

摘要

继发性骨质疏松症是骨质疏松症的常见病因,有许多与骨质疏松症相关的医学病症。其中许多病症在骨质疏松症发生之前就已经表现明显,了解这些先前存在的病症可能会影响是否进行骨质疏松症检测和/或治疗的决策。原因不明的骨质疏松症或脆性骨折史的男性和绝经前妇女应进行继发性骨质疏松症的检查。有继发性骨质疏松症风险因素的绝经后妇女也应仔细评估。除了与糖皮质激素的明确关联外,越来越多的药物也与骨丢失和骨折有关。通过适当考虑继发性原因和相关检查,许多这些病症都可以通过新的治疗方法预防。

相似文献

1
Secondary osteoporosis in patients with an osteoporotic fracture.骨质疏松性骨折患者的继发性骨质疏松症。
Best Pract Res Clin Rheumatol. 2009 Dec;23(6):769-79. doi: 10.1016/j.berh.2009.09.006.
2
The management of secondary osteoporosis.继发性骨质疏松症的管理
Best Pract Res Clin Rheumatol. 2005 Dec;19(6):1021-37. doi: 10.1016/j.berh.2005.06.005.
3
Osteoporosis risk in premenopausal women.绝经前女性的骨质疏松风险
Pharmacotherapy. 2009 Mar;29(3):305-17. doi: 10.1592/phco.29.3.305.
4
Osteoporosis and osteoporotic fractures in men: a clinical perspective.男性骨质疏松症及骨质疏松性骨折:临床视角
Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Jun;14(2):299-315. doi: 10.1053/beem.2000.0075.
5
Epidemiology, etiology, and diagnosis of osteoporosis.骨质疏松症的流行病学、病因学及诊断
Am J Obstet Gynecol. 2006 Feb;194(2 Suppl):S3-11. doi: 10.1016/j.ajog.2005.08.047.
6
Glucocorticoid-induced osteoporosis.糖皮质激素性骨质疏松症
Curr Opin Endocrinol Diabetes Obes. 2007 Dec;14(6):446-50. doi: 10.1097/MED.0b013e3282f15407.
7
Premenopausal osteoporosis: how to treat?绝经前骨质疏松症:如何治疗?
Reumatol Clin. 2012 Mar-Apr;8(2):93-7. doi: 10.1016/j.reuma.2011.05.011. Epub 2011 Aug 6.
8
Osteodensitometry in healthy postmenopausal women.健康绝经后女性的骨密度测定
Prescrire Int. 2008 Apr;17(94):68-72.
9
Strategies for treatment to prevent fragility fractures in postmenopausal women.治疗绝经后妇女脆性骨折的策略。
Best Pract Res Clin Rheumatol. 2009 Dec;23(6):727-40. doi: 10.1016/j.berh.2009.09.001.
10
Epidemiology of fractures and assessment of fracture risk.骨折的流行病学及骨折风险评估
Clin Lab Med. 2000 Sep;20(3):439-53.

引用本文的文献

1
Denosumab in the Management of Glucocorticoid-Induced Osteoporosis: Long-Term Efficacy and Secondary Fracture Outcomes.地诺单抗治疗糖皮质激素性骨质疏松症:长期疗效及继发性骨折结局
J Clin Med. 2025 Feb 27;14(5):1633. doi: 10.3390/jcm14051633.
2
Pyroptosis mediates osteoporosis via the inflammation immune microenvironment.焦亡通过炎症免疫微环境介导骨质疏松症。
Front Immunol. 2024 Jun 3;15:1371463. doi: 10.3389/fimmu.2024.1371463. eCollection 2024.
3
Bone Health in Adults With Prader-Willi Syndrome: Clinical Recommendations Based on a Multicenter Cohort Study.
成人普拉德-威利综合征的骨骼健康:基于多中心队列研究的临床建议。
J Clin Endocrinol Metab. 2022 Dec 17;108(1):59-84. doi: 10.1210/clinem/dgac556.
4
When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis.何时开始和停止使用骨保护药物预防糖皮质激素性骨质疏松症。
Front Endocrinol (Lausanne). 2021 Dec 15;12:782118. doi: 10.3389/fendo.2021.782118. eCollection 2021.
5
Adverse Effects of Long-Term Oral Corticosteroids in the Department of Dermatology, Antananarivo, Madagascar.长期口服皮质类固醇在马达加斯加塔那那利佛皮肤科的不良反应
Clin Cosmet Investig Dermatol. 2021 Sep 24;14:1337-1341. doi: 10.2147/CCID.S332201. eCollection 2021.
6
Endogenous Glucocorticoid Metabolism in Bone: Friend or Foe.骨内源性糖皮质激素代谢:是敌是友。
Front Endocrinol (Lausanne). 2021 Aug 27;12:733611. doi: 10.3389/fendo.2021.733611. eCollection 2021.
7
Prevalence of less severe hypercortisolism in fractured patients admitted in an outpatient clinic for metabolic bone diseases.骨折患者在代谢性骨病门诊就诊时,表现为较轻程度的皮质醇增多症。
Endocrine. 2021 Jul;73(1):203-208. doi: 10.1007/s12020-021-02616-1. Epub 2021 Jan 23.
8
Systemic immunosuppressive therapies for uveitis in developing countries.发展中国家葡萄膜炎的全身免疫抑制疗法。
Indian J Ophthalmol. 2020 Sep;68(9):1852-1862. doi: 10.4103/ijo.IJO_1548_20.
9
A Case of Short Stature and Severe Osteoporosis in a Young Man with Oculocutaneous Albinism: Syndrome or Coincidence?一名患有眼皮肤白化病的年轻男性出现身材矮小和严重骨质疏松症:综合征还是巧合?
Cureus. 2020 Apr 24;12(4):e7817. doi: 10.7759/cureus.7817.
10
Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases.药物性骨质疏松/骨软化症:法国和西班牙药品不良反应数据库分析。
Eur J Clin Pharmacol. 2019 Dec;75(12):1705-1711. doi: 10.1007/s00228-019-02743-9. Epub 2019 Aug 29.